OBJECTIVE: To investigate the therapeutic effect of Duoxikang capsula (DXK) on hyperlipoidemia in children with the steroid sensitive nephrotic syndrome (SSNS). METHODS: Twenty SSNS children were randomly divided into a DXK treated group and a control group. DXK was then administered (45 mg/kg weight daily) in the DXK treated group and the same regular steroid therapeutic measurements were conducted in two groups of SSNS. Bloodlipoid compliments were determined, including total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C) and low density lipoproteincholesterol (LDL-C) before the randomization, and again 2～3 weeks, 5～6 weeks, 8～10 weeks after the treatment. RESULTS: During the 2～3 weeks, levels of LDL-C ［(3.19±2.08) mmol and TC ［(6.42±2.04) mmol］ in the DXKtreated group were markedly lower than those in the control group ［(5.82±2.73) mmol, (10.0±4.75) mmol, respectively］ (both P<0.05). During the 5～6 weeks and 8～10 weeks, the level of LDL-C in the DXK treated group was also lower than that in the control group ［(2.83±1.50) mmol vs (4.94±2.04) mmol; (2.30±0.46) mmol vs (4.20±2.22) mmol, respectively. P<0.01 . CONCLUSIONS: DXK treatment reduced severe hyperlipoidemia, especially LDL-C in children with SSNS. It is suggested that DXK treatment may reduce the secondary renal injury in these children.